Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Trial Profile

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms GENEVIEVE
  • Most Recent Events

    • 30 Jul 2017 Results published in the European Journal of Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 17 Nov 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top